Beate Ritz1, Pei-Chen Lee2, Christina F Lassen2, Onyebuchi A Arah2. 1. From the Department of Epidemiology (B.R., O.A.A.), University of California at Los Angeles School of Public Health; Department of Neurology (B.R.), School of Medicine, University of California at Los Angeles; Department of Health Care Management (P.-C.L.), College of Healthcare Administration and Management, National Taipei University of Nursing Health Sciences, Taiwan; and Danish Cancer Society Research Center (C.F.L.), Danish Cancer Society, Copenhagen, Denmark. britz@ucla.edu. 2. From the Department of Epidemiology (B.R., O.A.A.), University of California at Los Angeles School of Public Health; Department of Neurology (B.R.), School of Medicine, University of California at Los Angeles; Department of Health Care Management (P.-C.L.), College of Healthcare Administration and Management, National Taipei University of Nursing Health Sciences, Taiwan; and Danish Cancer Society Research Center (C.F.L.), Danish Cancer Society, Copenhagen, Denmark.
Abstract
OBJECTIVE: To assess whether being able to quit smoking is an early marker of Parkinson disease (PD) onset rather than tobacco being "neuroprotective," we analyzed information about ease of quitting and nicotine substitute use. METHODS: For this case-control study, we identified 1,808 patients with PD diagnosed between 1996 and 2009 from Danish registries, matched 1,876 population controls on sex and year of birth, and collected lifestyle information. We estimated odds ratios and 95% confidence intervals with logistic regression adjusting for matching factors and confounders. RESULTS: Fewer patients with PD than controls ever established a smoking habit. Among former smokers, those with greater difficulty quitting or using nicotine substitutes were less likely to develop PD, with the risk being lowest among those reporting "extremely difficult to quit" compared with "easy to quit." Nicotine substitute usage was strongly associated with quitting difficulty and duration of smoking, i.e., most strongly among current smokers, followed by former smokers who had used nicotine substitutes, and less strongly among former smokers who never used substitutes. CONCLUSIONS: Our data support the notion that patients with PD are able to quit smoking more easily than controls. These findings are compatible with a decreased responsiveness to nicotine during the prodromal phase of PD. We propose that ease of smoking cessation is an aspect of premanifest PD similar to olfactory dysfunction, REM sleep disorders, or constipation and suggests that the apparent "neuroprotective" effect of smoking observed in epidemiologic studies is due to reverse causation.
OBJECTIVE: To assess whether being able to quit smoking is an early marker of Parkinson disease (PD) onset rather than tobacco being "neuroprotective," we analyzed information about ease of quitting and nicotine substitute use. METHODS: For this case-control study, we identified 1,808 patients with PD diagnosed between 1996 and 2009 from Danish registries, matched 1,876 population controls on sex and year of birth, and collected lifestyle information. We estimated odds ratios and 95% confidence intervals with logistic regression adjusting for matching factors and confounders. RESULTS: Fewer patients with PD than controls ever established a smoking habit. Among former smokers, those with greater difficulty quitting or using nicotine substitutes were less likely to develop PD, with the risk being lowest among those reporting "extremely difficult to quit" compared with "easy to quit." Nicotine substitute usage was strongly associated with quitting difficulty and duration of smoking, i.e., most strongly among current smokers, followed by former smokers who had used nicotine substitutes, and less strongly among former smokers who never used substitutes. CONCLUSIONS: Our data support the notion that patients with PD are able to quit smoking more easily than controls. These findings are compatible with a decreased responsiveness to nicotine during the prodromal phase of PD. We propose that ease of smoking cessation is an aspect of premanifest PD similar to olfactory dysfunction, REM sleep disorders, or constipation and suggests that the apparent "neuroprotective" effect of smoking observed in epidemiologic studies is due to reverse causation.
Authors: Ronald B Postuma; Dag Aarsland; Paolo Barone; David J Burn; Christopher H Hawkes; Wolfgang Oertel; Tjalf Ziemssen Journal: Mov Disord Date: 2012-04-15 Impact factor: 10.338
Authors: G Webster Ross; Helen Petrovitch; Robert D Abbott; Caroline M Tanner; Jordan Popper; Kamal Masaki; Lenore Launer; Lon R White Journal: Ann Neurol Date: 2008-02 Impact factor: 10.422
Authors: Thorgeir E Thorgeirsson; Daniel F Gudbjartsson; Ida Surakka; Jacqueline M Vink; Najaf Amin; Frank Geller; Patrick Sulem; Thorunn Rafnar; Tõnu Esko; Stefan Walter; Christian Gieger; Rajesh Rawal; Massimo Mangino; Inga Prokopenko; Reedik Mägi; Kaisu Keskitalo; Iris H Gudjonsdottir; Solveig Gretarsdottir; Hreinn Stefansson; John R Thompson; Yurii S Aulchenko; Mari Nelis; Katja K Aben; Martin den Heijer; Asger Dirksen; Haseem Ashraf; Nicole Soranzo; Ana M Valdes; Claire Steves; André G Uitterlinden; Albert Hofman; Anke Tönjes; Peter Kovacs; Jouke Jan Hottenga; Gonneke Willemsen; Nicole Vogelzangs; Angela Döring; Norbert Dahmen; Barbara Nitz; Michele L Pergadia; Berta Saez; Veronica De Diego; Victoria Lezcano; Maria D Garcia-Prats; Samuli Ripatti; Markus Perola; Johannes Kettunen; Anna-Liisa Hartikainen; Anneli Pouta; Jaana Laitinen; Matti Isohanni; Shen Huei-Yi; Maxine Allen; Maria Krestyaninova; Alistair S Hall; Gregory T Jones; Andre M van Rij; Thomas Mueller; Benjamin Dieplinger; Meinhard Haltmayer; Steinn Jonsson; Stefan E Matthiasson; Hogni Oskarsson; Thorarinn Tyrfingsson; Lambertus A Kiemeney; Jose I Mayordomo; Jes S Lindholt; Jesper Holst Pedersen; Wilbur A Franklin; Holly Wolf; Grant W Montgomery; Andrew C Heath; Nicholas G Martin; Pamela A F Madden; Ina Giegling; Dan Rujescu; Marjo-Riitta Järvelin; Veikko Salomaa; Michael Stumvoll; Tim D Spector; H-Erich Wichmann; Andres Metspalu; Nilesh J Samani; Brenda W Penninx; Ben A Oostra; Dorret I Boomsma; Henning Tiemeier; Cornelia M van Duijn; Jaakko Kaprio; Jeffrey R Gulcher; Mark I McCarthy; Leena Peltonen; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nat Genet Date: 2010-04-25 Impact factor: 38.330
Authors: Beate Ritz; Alberto Ascherio; Harvey Checkoway; Karen S Marder; Lorene M Nelson; Walter A Rocca; G Webster Ross; Daniel Strickland; Stephen K Van Den Eeden; Jay Gorell Journal: Arch Neurol Date: 2007-07
Authors: Sudhakar R Subramaniam; Iddo Magen; Nicholas Bove; Chunni Zhu; Vincent Lemesre; Garima Dutta; Chris Jean Elias; Henry A Lester; Marie-Francoise Chesselet Journal: Neurobiol Dis Date: 2018-06-01 Impact factor: 5.996